Nexien BioPharma (NXEN) 10-K 28 Sep 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2018	Sep. 25, 2018	Dec. 31, 2017
Document And Entity Information
Entity Registrant Name	NEXIEN BIOPHARMA, INC.
Entity Central Index Key	1,625,288
Document Type	10-K
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 65,310,424
Entity Common Stock, Shares Outstanding		44,448,496
Trading Symbol	NTVA
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Current Assets
Cash	$ 819,739	$ 242,778
Due from related party	15,000	141,329
Total current assets	834,739	384,107
Due from related party - non-current	99,667
Deposit for acquisition of Kinder Holdings Corp.		86,670
License	337,915	302,915
Total Assets	1,272,321	773,692
Current Liabilities
Accounts payable and accrued expenses	88,785	210,405
Total current liabilities	88,785	210,405
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $.0001 par value; 10,000,000 authorized; none issued
Common stock-$.0001 par value; 200,000,000 shares authorized; 44,448,496 shares issued and outstanding -June 30, 2018; and 32,615,112 shares- June 30, 2017	4,445	3,262
Additional paid in capital	2,882,888	1,235,457
Common stock subject to forfeiture	(229,168)
Common stock subscription receivable		(484,000)
Accumulated deficit	(1,474,629)	(191,432)
Total Stockholders' Equity	1,183,536	563,287
Total Liabilities and Stockholders' Equity	$ 1,272,321	$ 773,692

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Jun. 30, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Common stock, par value	$ .0001	$ .0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	44,448,496	32,615,112
Common stock, shares outstanding	44,448,496	32,615,112

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2018
Income Statement [Abstract]
Revenue
Operating expenses
Professional fees	170,661	392,969
Research and development	12,261	116,791
General and administrative	8,510	773,437
Total operating expenses	191,432	1,283,197
Net loss	$ (191,432)	$ (1,283,197)
Loss per share - basic and diluted	$ (0.01)	$ (0.03)
Weighted average shares outstanding - basic and diluted	24,421,427	42,668,066

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Comon Stock Subject to Forfeiture [Member]	Subscription Receivable [Member]	Accumulated Deficit [Member]	Total
Balance at Mar. 26, 2017
Balance shares at Mar. 26, 2017
Stock issued for costs and expenses at $0.0084 per share to founders	$ 2,400	198,828				201,228
Stock issued for costs and expenses at $0.0084 per share to founders, shares	24,000,000
Stock issued for cash at $0.1125	$ 83	93,417				93,500
Stock issued for cash at $0.1125, shares	831,112
Share issuance costs		(6,545)				(6,545)
Stock issued for cash at $0.125	$ 779	972,221		(484,000)		489,000
Stock issued for cash at $0.125, shares	7,784,000
Share issuance costs		(22,464)				(22,464)
Net loss					(191,432)	(191,432)
Balance at Jun. 30, 2017	$ 3,262	1,235,457		(484,000)	(191,432)	563,287
Balance shares at Jun. 30, 2017	32,615,112
Stock issued for cash at $0.125	$ 338	422,162				422,500
Stock issued for cash at $0.125, shares	3,380,000
Proceeds from subscription receivable				484,000		484,000
Issuance of shares to management at $0.125 per share	$ 640	799,360	(533,334)			266,666
Issuance of shares to management at $0.125 per share, shares	6,400,000
Issuance of stock for consulting services at $0.125	$ 44	55,306				55,350
Issuance of stock for consulting services at $0.125, shares	442,800
Stock issued for cash at $0.25	$ 10	24,990				25,000
Stock issued for cash at $0.25, shares	100,000
Share issuance costs		(4,917)				(4,917)
Recapitalization of Kinder Holder	$ 85	(99,655)				(99,570)
Recapitalization of Kinder Holder, shares	852,051
Vesting of management shares subject to forfeiture			158,333			158,333
Cancellation of management shares	$ (116)	(145,717)	145,833
Cancellation of management shares, shares	(1,166,667)
Stock issued for cash at $1.05	$ 2	25,198				25,200
Stock issued for cash at $1.05, shares	24,000
Issuance of stock for warrant exercise at $0.25 per share	$ 96	240,004				240,100
Issuance of stock for warrant exercise at $0.25 per share, shares	960,400
Issuance of stock for warrant exercise at $0.38 per share	$ 75	283,709				283,784
Issuance of stock for warrant exercise at $0.38 per share, shares	746,800
Issuance of stock for warrant exercise at $0.50 per share	$ 9	46,991				47,000
Issuance of stock for warrant exercise at $0.50 per share, shares	94,000
Net loss					(1,283,197)	(1,283,197)
Balance at Jun. 30, 2018	$ 4,445	$ 2,882,888	$ (229,168)		$ (1,474,629)	$ 1,183,536
Balance shares at Jun. 30, 2018	44,448,496

Consolidated Statement of Stoc6

Consolidated Statement of Stockholders' Equity (Parenthetical) - $ / shares	Jun. 30, 2018	Jun. 30, 2017
Consulting Services [Member]
Shares issued price per share	$ 0.125
Founders [Member]
Shares issued price per share		$ 0.0084
Management [Member]
Shares issued price per share	0.125
Common Stock One [Member]
Shares issued price per share		0.1125
Common Stock Two [Member]
Shares issued price per share	0.125	$ 0.125
Common Stock Three [Member]
Shares issued price per share	0.25
Common Stock Four [Member]
Shares issued price per share	1.05
Warrant One [Member]
Warrant exercise price per share	0.25
Warrant Two [Member]
Warrant exercise price per share	0.38
Warrant Three [Member]
Warrant exercise price per share	$ 0.50

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2018
Cash flows from operating activities
Net loss	$ (191,432)	$ (1,283,197)
Adjustments to reconcile net loss to net cash used in operating activities
Stock based compensation		480,349
Changes is assets and liabilities
Decrease (increase) in due from related party	(138,330)	26,662
(Decrease) increase in accounts payable and accrued expenses	148,255	(99,156)
Cash used in operating activities	(181,507)	(875,342)
Cash flows from investing activities
Cash paid for license	(65,000)	(35,000)
Cash paid for acquisition deposit	(86,670)	(12,900)
Cash used in investing activities	(151,670)	(47,900)
Cash flows from financing activities
Cash proceeds from issuance of common stock	582,500	1,527,583
Payment of offering costs	(6,545)	(27,380)
Cash provided by financing activities	575,955	1,500,203
Net increase in cash and cash equivalents	242,778	576,961
Cash and cash equivalents, beginning of period		242,778
Cash and cash equivalents, end of period	242,778	819,739
Supplemental disclosure of non-cash investing and financing activities
Shares issued for Kinder Exchange		99,570
Issuance of common stock to related party for costs and expenses	201,228
Unpaid license costs	65,000
Unpaid offering costs	$ 22,464

Nature of Business and Basis of

Nature of Business and Basis of Presentation	12 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Note 1 – Nature of Business and Basis of Presentation The Company was incorporated on November 10, 1952 in Michigan as Gantos, Inc. On July 21, 2008, the Company completed its change in domicile to Delaware and subsequently changed its name to Kinder Holding Corp. (the “Company”). As of October 13, 2017, the Company completed a reverse acquisition of Intiva BioPharma Inc., a Colorado corporation (“BioPharma”) through an exchange of shares (the “Share Exchange Transaction”). In connection with the Share Exchange Transaction, the Company changed its name to Intiva BioPharma Inc. on November 8, 2017 and, in September 2018, the Company changed its name to Nexien BioPharma, Inc. As further described in Note 3, BioPharma became a wholly-owned subsidiary of the Company. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). The operations of BioPharma were the only continuing operations of the Company. The accompanying financial statements as of June 30, 2018 and 2017 and for the periods then ended present the historical financial information of BioPharma. BioPharma was incorporated under the laws of the State of Colorado on March 27, 2017 to pursue pre-clinical and drug development activities, in accordance with U.S. Food and Drug Administration (“FDA”) protocols, for certain pharmaceutical formulations that include cannabinoids. It is pursuing the formulation and development of cannabinoid-based drugs for medical conditions and disorders, and owns a license covering certain intellectual property, including certain patent applications, and has filed five of its own provisional patent applications for other drugs that include cannabinoids and other substances, including terpenes, that are intended to be developed with the objective of treating certain medical conditions and disorders. It was formed as a corporate subsidiary of the Colorado corporation Intiva USA Inc. (“Intiva USA”), which is a subsidiary of the Ontario, Canada corporation, INTIVA Inc., now known as Kanativa Inc. All share and per share amounts have been adjusted in the footnotes and accompanying financial statements to give effect to the Share Exchange Transaction. Principles of Consolidation The accompanying consolidated financial statements include BioPharma and its wholly owned subsidiaries: Intiva BioPharma Inc. (a Colorado corporation), Intiva Kotzker Pharmaceuticals Inc. (“Intiva Kotzker”) and Intiva Sharir Inc., and were prepared from the accounts of the Company in accordance with accounting principles generally accepted in the United States of America (US GAAP). All significant intercompany transactions and balances have been eliminated on consolidation. Basis of Presentation/Going Concern Uncertainty All share and per share amounts have been adjusted in the footnotes and accompanying financial statements to give effect to the Share Exchange Transaction. (See Note 3). The accompanying financial statements have been prepared in conformity with US GAAP, which contemplates continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception of $1,474,629. The development of pharmaceuticals with the objective of obtaining approval by the FDA and other international regulatory authorities is not a short-term endeavor for any specific drug candidate. It also requires extremely significant amounts of capital funding for clinical trials and other matters. At June 30, 2018, the Company had working capital of $745,954. The Company will require significant additional capital to fund the implementation and execution of its business plan. This capital, which likely will be millions of dollars for a single drug candidate, will be required for research, regulatory applications, and clinical trials. At the present time, the Company does not have any commitments or known sources for this level of funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at June 30, 2018 and 2017. Valuation of Long-Lived Assets The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations. Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At June 30, 2018 and 2017, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The assets or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended June 30, 2018 and 2017, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As of June 30, 2018, no assets or liabilities were required to be measured at fair value on a recurring basis. Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Certain estimates and judgments must be made in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of the Company’s net deferred tax assets is dependent upon generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. Management has determined it more likely than not that these timing differences will not materialize and has provided a valuation allowance against substantially all the Company’s net deferred tax assets. Management will continue to evaluate the realization of the deferred tax assets and its related valuation allowance. If assessment of the deferred tax assets or the corresponding valuation allowance were to change, the Company would record the related adjustment to income during the period in which the determination is made. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. Liabilities for anticipated tax audit issues in the U.S. are recognized based on the estimate of whether, and to the extent to which, additional taxes will be due. If it is ultimately determined that payment of these amounts is unnecessary, the liability will be reversed and a tax benefit will be recognized during the period in which it is determined that the liability is no longer necessary. The Company will record an additional charge to the provision for taxes in the period in which it is determined that the recorded tax liability is less than the Company expects the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Research and Development Expenses Research and development expenses are charged to operations as incurred. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk. Stock-based compensation Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values. Issuance of shares for non-cash consideration The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Reclassifications Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current year periods presentation. Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, “Distinguishing Liabilities from Equity,” because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently unable to determine the impact on its consolidated financial statements of the adoption of this new accounting pronouncement. Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations.

Share Exchange Agreement and Ac

Share Exchange Agreement and Acquisition Deposit	12 Months Ended
	Jun. 30, 2018
Business Combinations [Abstract]
Share Exchange Agreement and Acquisition Deposit	Note 3 – Share Exchange Agreement and Acquisition Deposit On August 8, 2017, the Company entered into a Share Exchange Agreement, as amended and restated on October 13, 2017, (the “Agreement”), with BioPharma. Pursuant to the terms of the Agreement, the Company agreed to issue to the shareholders of BioPharma 42,642,712 post-reverse stock-split shares of the Company’s common stock, par value $0.0001 (“Common Stock”), in exchange for all of the issued and outstanding shares of BioPharma capital stock, thereby making BioPharma a wholly-owned subsidiary of the Company. As part of the Closing of the Agreement, the 20,000,000 pre-reverse split shares of the Company’s Common Stock previously purchased by Intiva USA, effective on June 26, 2017 in a change in control transaction from the Company’s control shareholders, were canceled. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). In June 2017, pursuant to a Debt Purchase Agreement, BioPharma paid $86,670 to a director of the Company to satisfy the Company’s debt obligation to the director and for BioPharma to purchase the debt obligation. The amount paid and additional costs paid by BioPharma on behalf of the Company subsequent to June 30, 2017 of $12,900 aggregated $99,570, was classified as a non-current asset on the accompanying June 30, 2017 consolidated balance sheet, and in October 2017 was exchanged as consideration for shares issued in the Agreement.

License Agreements

License Agreements	12 Months Ended
	Jun. 30, 2018
License Agreements
License Agreements	Note 4 – License Agreements In March 2017, Intiva Kotzker licensed certain intellectual property from Kotzker Consulting LLC (“Kotzker Consulting”), an unrelated entity. The licensed intellectual property includes patent applications relating to the use of cannabinoid receptor modulators and terpenes in the acute treatment during exposure to organophosphorus nerve agents and/or organophosphorus insecticides. Under terms of the agreement, Intiva Kotzker shall use its commercially reasonable efforts to develop and commercialize the licensed products, and, in particular, will be responsible for the design, manufacturing, preclinical, clinical, and regulatory development activities of the licensed products and shall bear the costs of such activities. As consideration for entering into the agreement, Intiva Kotzker agreed to: (i) pay Kotzker Consulting $180,000, (ii) pay patent prosecution costs incurred as of the date of the agreement of $15,000 and (iii) issue to Kotzker Consulting 31,550 shares of Intiva Inc.’s common stock valued at $78,875 ($2.50 per share based on recent private placement to third parties of Intiva Inc.’s common stock). The Company has capitalized legal fees of $29,040 incurred in conjunction with acquiring the license agreement, As of June 30, 2017, $65,000 was due under the license agreement, which amount was paid in August 2017. The total value ascribed to the License Agreement with Kotzker Consulting is $302,915. The license agreement terminates, on a country by country basis, upon the expiration of the licensed patent for the licensed intellectual property, or when a competitor generic product utilizing the licensed technology is marketed in the particular country. Intiva Kotzker shall be responsible for development milestone payments for (i) licensed products for use as a preventative and therapeutic neuroprotective against nerve agents and pesticides and (ii) licensed products for treatment of diseases. Milestone payments for each of the foregoing will each be due in two payments, the first payment no later than thirty (30) days from acceptance of submission of the regulatory filing of the first licensed product and the second payment no later than thirty (30) days from approval of the first licensed product. Royalties will be due beginning with first commercial sale of developed products. The Company has completed and submitted a Pre-Investigational New Drug meeting request and amendment thereto with the FDA. In September 2017, BioPharma entered into a contract with a contract manufacturing organization to develop an injectable formulation of a drug product to be submitted to the FDA. It is anticipated that the product will be developed utilizing the new drug application 505(b) (2) regulatory pathway for use in the treatment during and immediately following exposure to organophosphorus nerve agents. The drug product is to consist of a synthetic cannabinoid and a blend of terpenes in an injectable vehicle. On February 28, 2018, the Company obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications. Upon execution of the agreement, $35,000 was paid to the licensor, and payments of $30,000 and $35,000 were required by August 31, 2018 and February 28, 2019, respectively. On September 18, 2018, the agreement was amended to provide for (i) extension of the payment of the fee due August 31, 2018 provided that licensor receive $10,000 on November 1, 2018 and the remaining $20,000 on February 28, 2019 and (ii) extension of the remaining $35,000 fee due February 28, 2019 to August 31, 2019. The Company is required to pay milestone payments upon obtaining regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products. The Company may grant sublicenses under the terms of the agreement.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Stockholders' Equity	Note 5 – Stockholders’ Equity Common stock In March 2017, the Company issued 24,000,000 shares of its Common Stock to Intiva USA as consideration for costs and expenses paid by Intiva USA on behalf of BioPharma and Intiva Kotzker aggregating $201,228. In May 2017, a private placement of 831,112 shares of BioPharma’s Common Stock was completed at a price of $0.1125 per share, for total proceeds of $93,500, to three non-affiliates of BioPharma. One of the non-affiliate investors in the May 2017 private placement subsequently became a director and officer of BioPharma. Offering costs associated with the private placement of $6,545 were recorded against the gross proceeds received from the offering. In May 2017, BioPharma commenced a private placement of 1,116,400 units of Common Stock and Warrants at a price of $1.25 per unit. Each unit consisted of ten shares of Common Stock, one Class A Warrant to purchase one share of Common Stock at $0.25 per share, one Class B Warrant to purchase one share of Common Stock at $0.38 per share and one Class C Warrant to purchase one share of Common Stock at $0.50 per share. As of June 30, 2017, 778,400 units (representing 7,784,00 common shares) had been sold, for total gross proceeds of $973,000, including 387,200 units which were subscribed but for which funds had not been received. The 3,872,000 shares underlying the subscribed units in the amount of $484,000 were included as issued and outstanding shares at June 30, 2017, and the related $484,000 subscription receivable was recorded as a component of stockholders’ equity on the June 30, 2017 consolidated balance sheet. Subsequent to June 30, 2017, the Company received proceeds of $484,000 for the subscribed shares. In July and August 2017, BioPharma sold an additional 338,000 units (representing 3,380,000 common shares) for gross proceeds of $422,500. On August 10, 2017, BioPharma adopted the “2017 Stock Incentive Plan” and granted an aggregate of 6,400,000 shares of Common Stock to five officers and directors of the Company, valued at $800,000 ($0.125 per share). One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017. In March 2018, the Company cancelled 1,166,667 unvested shares previously issued to its former CEO. As of June 30, 2018, 1,833,341 of the shares issued (valued at $229,168) are subject to forfeiture until vesting occurs. On August 25, 2017, BioPharma entered into consulting agreements with two unrelated individuals for (i) developing and maintaining social media portals and (ii) identifying and developing potential strategic partners for the Company’s various drug development activities. The agreements are each for a three-month term, payable monthly in shares of the Company’s Common Stock, valued at $0.125 per share, of an aggregate 304,800 shares and 138,000 shares, respectively. The Company has issued an aggregate 442,800 shares of Common Stock to the two individuals, valued at $55,350, representing all amounts due pursuant to the consulting agreements. On September 1, 2017, BioPharma completed a private placement sale of its common stock at $0.25 per share. The Company sold 100,000 shares for gross proceeds of $25,000, before offering costs of $4,917. In January 2018, BioPharma completed a unit private placement of Common Stock and Warrants at a price of $2.10 per unit. Each Unit consisted of two shares of Common Stock and one Warrant to purchase an additional share of common stock at a price of $2.90 per share for a term of six months commencing with the date of acceptance of the underlying subscription agreement. The Company received proceeds of $25,200 from the sale of 12,000 units (24,000 shares). During the year ended June 30, 2018, the Company issued 1,801,200 shares of Common Stock from the exercise of warrants from the May 2017 private placement of units as follows: Number Exercise Price Gross Proceeds Class A 960,400 $ 0.25 $ 240,100 Class B 746,800 $ 0.38 $ 283,784 Class C 94,000 $ 0.50 $ 47,000 Warrants The Company has issued warrants to investors in a series of subscription agreements in equity financings. The relative fair value of the warrants attached to the Common Stock issued in the May 2017 private placement of units was estimated at the date of grant using the Black-Sholes pricing model. The relative fair value attached to the Common Stock component is $1,139,573 and the relative fair value of the warrants is $255,927 as of the grant date. As of June 30, 2018, all unexcised Class A and Class B warrants expired by their terms. The relative fair value of the warrants attached to the common stock issued in the January 2018 private placement of units was estimated at the date of grant using the Black-Sholes pricing model. The relative fair value attached to the Common Stock component is $19,762 and the relative fair value of the warrants is $5,438 as of the grant date. The 12,000 warrants issued in the January 2018 private placement expired unexercised in July 2018. A summary of warrant activity during the year ended June 30, 2018 and initial period ended June 30, 2017 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Inception – March 27, 2017 - Granted 2,335,200 $ .38 Exercised - Expired - Outstanding and exercisable – June 30, 2017 2,335,200 $ .38 .53 Granted 1,026,000 $ .41 Exercised (1,801,200 ) $ .32 Expired (525,600 ) $ .34 Outstanding and exercisable – June 30, 2018 1,034,400 $ .53 .1 The following table summarizes information about warrants outstanding at June 30, 2018: Issuance Number Exercise Price Expires January 2018 Placement 12,000 $ 2.90 July 15, 2018 May 2017 – Class C 1,022,400 $ 0.50 August 8, 2018 2018 Equity Incentive Plan On March 30, 2018, the Company’s board of directors approved and recommended for adoption by the stockholders of the Company a 2018 Equity Incentive Plan and has reserved 8,000,000 shares of Common Stock for issuance under the terms of that Plan.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions BioPharma was formed as a subsidiary of Intiva USA, which is a subsidiary of Kanativa Inc. Intiva USA was issued 24,000,000 shares of BioPharma’s common stock as consideration for its contribution of 100% of the ownership of Intiva Kotzker, and costs and expenses incurred on behalf of BioPharma and Intiva Kotzker in the amount of $201,228. Included in the consideration for the issuance of the common stock is $172,915 of capitalized license agreement costs comprised of (i) the value of Intiva Inc. common stock issued to Kotzker Consulting of $78,875 and (ii) payments to Kotzker Consulting and legal costs in the aggregate of $94,040 (See Note 4). At June 30, 2017, BioPharma was owed $141,329 from Intiva USA for advances made by BioPharma on behalf of Intiva USA in conjunction with the Share Exchange Agreement (See Note 3). During the year ended June 30, 2018, $26,662 was repaid by Intiva USA. The balance due from Intiva USA at June 30, 2018 of $114,667 will be repaid at $1,500 per month for 18 months commencing September 1, 2018 with the remaining balance due on March 1, 2020. On August 10, 2017, the Company granted an aggregate of 6,400,000 shares of Common Stock to five officers and directors of the Company, valued at $800,000 ($0.125 per share), under the Company’s 2017 Stock Incentive Plan. One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017. In March 2018, the Company cancelled 1,166,667 unvested shares previously issued to its former CEO. As of June 30, 2018, 1,833,341 of the shares issued (valued at $229,168) are subject to forfeiture until vesting occurs. The Company’s Chairman and Chief Financial Officer are also officers of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 – Income Taxes The Company accounts for income taxes in accordance with standards of disclosure propounded by the FASB, and any related interpretations of those standards sanctioned by the FASB. Accordingly, deferred tax assets and liabilities are determined based on differences between the financial statement and tax bases of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. No provision for income taxes has been recorded due to the net operating loss carryforwards totaling approximately $1,534,000 as of June 30, 2018 that will be offset against future taxable income. The available net operating loss carry forwards expire in various years through 2038. No tax benefit has been reported in the financial statements because the Company believes there is a 50% or greater chance the carry forwards will expire unused. There were no uncertain tax positions taken by the Company. The deferred tax asset and valuation account is as follows at June 30: 2018 2017 Deferred tax asset: Net operating loss carryforward $ 568,734 $ 70,945 Valuation allowance (568,734 ) (70,945 ) Total $ - $ - The components of income tax expense are as follows for the years ended June 30: 2018 2017 Change in net operating loss benefit $ 497,789 $ 70,945 Change in valuation allowance (497,789 ) (70,945 ) Total $ - $ -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies At June 30, 2018, there were no legal proceedings against the Company.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events 2017 Stock Incentive Plan On July 25, 2018, the Company accelerated the vesting of 1,083,342 unvested shares of Common Stock previously granted to its Chief Executive Officer and Chief Financial Officer. Warrants On July 27, 2018, Company extended the expiration date of its Class C Warrants, from July 27, 2018, to August 8, 2018, and also offered holders of the Class C Warrants who did not wish to exercise their warrants the opportunity to exchange their Class C Warrants for new warrants. Each new warrant, denominated as Class D, is exercisable through September 28, 2018 (subsequently extended to November 30, 2018) to purchase one unit for $1.00, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock at a price of $2.00 per share through January 31, 2019. Holders of 976,400 Class C warrants were issued Class D warrants. On September 12, 2018, the Company authorized the issuance of 94,000 Class E warrants to those shareholders who exercised their Class C warrants and did not exchange them for Class D warrants. Each Class E warrant is exercisable to purchase one share of common stock at a price of $2.00 per share through January 31, 2019. 2018 Equity Incentive Plan In July 2018, the Board of Directors granted options to purchase a total of 1,810,000 shares of Common Stock, exercisable for a period of seven years, to officers/directors/consultants of the Company at an exercise price of $0.54 per share. In August 2018, the Board of Directors granted options to purchase a total of 150,000 shares of Common Stock, exercisable for a period of seven years, to two individuals, (i)a director and (ii) a consultant of the Company, at an exercise price of $0.38 per share.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at June 30, 2018 and 2017.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At June 30, 2018 and 2017, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.
Fair Value Measurements	Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The assets or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended June 30, 2018 and 2017, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As of June 30, 2018, no assets or liabilities were required to be measured at fair value on a recurring basis.
Earnings Per Common Share	Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
Income Taxes	Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Certain estimates and judgments must be made in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of the Company’s net deferred tax assets is dependent upon generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. Management has determined it more likely than not that these timing differences will not materialize and has provided a valuation allowance against substantially all the Company’s net deferred tax assets. Management will continue to evaluate the realization of the deferred tax assets and its related valuation allowance. If assessment of the deferred tax assets or the corresponding valuation allowance were to change, the Company would record the related adjustment to income during the period in which the determination is made. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. Liabilities for anticipated tax audit issues in the U.S. are recognized based on the estimate of whether, and to the extent to which, additional taxes will be due. If it is ultimately determined that payment of these amounts is unnecessary, the liability will be reversed and a tax benefit will be recognized during the period in which it is determined that the liability is no longer necessary. The Company will record an additional charge to the provision for taxes in the period in which it is determined that the recorded tax liability is less than the Company expects the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to operations as incurred.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk.
Stock-Based Compensation	Stock-based compensation Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values.
Issuance of Shares for Non-Cash Consideration	Issuance of shares for non-cash consideration The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
Reclassifications	Reclassifications Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current year periods presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, “Distinguishing Liabilities from Equity,” because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently unable to determine the impact on its consolidated financial statements of the adoption of this new accounting pronouncement. Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Schedule of Warrants Exercised	During the year ended June 30, 2018, the Company issued 1,801,200 shares of Common Stock from the exercise of warrants from the May 2017 private placement of units as follows: Number Exercise Price Gross Proceeds Class A 960,400 $ 0.25 $ 240,100 Class B 746,800 $ 0.38 $ 283,784 Class C 94,000 $ 0.50 $ 47,000
Summary of Warrant Activity	A summary of warrant activity during the year ended June 30, 2018 and initial period ended June 30, 2017 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Inception – March 27, 2017 - Granted 2,335,200 $ .38 Exercised - Expired - Outstanding and exercisable – June 30, 2017 2,335,200 $ .38 .53 Granted 1,026,000 $ .41 Exercised (1,801,200 ) $ .32 Expired (525,600 ) $ .34 Outstanding and exercisable – June 30, 2018 1,034,400 $ .53 .1
Schedule of Warrants Outstanding	The following table summarizes information about warrants outstanding at June 30, 2018: Issuance Number Exercise Price Expires January 2018 Placement 12,000 $ 2.90 July 15, 2018 May 2017 – Class C 1,022,400 $ 0.50 August 8, 2018

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Asset	The deferred tax asset and valuation account is as follows at June 30: 2018 2017 Deferred tax asset: Net operating loss carryforward $ 568,734 $ 70,945 Valuation allowance (568,734 ) (70,945 ) Total $ - $ -
Schedule of Components of Income Tax Expense	The components of income tax expense are as follows for the years ended June 30: 2018 2017 Change in net operating loss benefit $ 497,789 $ 70,945 Change in valuation allowance (497,789 ) (70,945 ) Total $ - $ -

Nature of Business and Basis 20

Nature of Business and Basis of Presentation (Details Narrative)	15 Months Ended
	Jun. 30, 2018USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating loss	$ (1,474,629)
Working capital	$ 745,954

Share Exchange Agreement and 21

Share Exchange Agreement and Acquisition Deposit (Details Narrative) - USD ($)	Aug. 08, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2018
Common stock par value		$ .0001	$ .0001	$ .0001
Deposit for acquisition		$ 86,670	$ 86,670
Cash paid for acquisition deposit			86,670	12,900
Shares issued for Kinder Exchange				$ 99,570
Share Exchange Agreement [Member] | Post-Reverse Stock-Split [Member]
Reverse stock-split shares	42,642,712
Common stock par value	$ 0.0001
Share Exchange Agreement [Member] | Pre-Reverse Split [Member]
Reverse stock-split shares	20,000,000
Debt Purchase Agreement [Member] | Director [Member]
Deposit for acquisition		86,670	$ 86,670
Cash paid for acquisition deposit		12,900
Shares issued for Kinder Exchange		$ 99,570

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)	Feb. 28, 2018	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2018	Aug. 31, 2017
Value of common stock shares			$ 201,228
License cost		$ 302,915	302,915	$ 337,915
Payment to license	$ 35,000		65,000	35,000
August 31, 2018 [Member]
Payment to license				30,000
February 28, 2019 [Member]
Payment to license				35,000
November 1, 2018 [Member]
Payment to license				10,000
February 28, 2019 [Member]
Payment to license				20,000
February 28, 2019 to August 31, 2019 [Member]
Payment to license				$ 35,000
License Agreement [Member]
Due to related party					$ 65,000
Kotzker Consulting LLC [Member]
Due to related party		180,000	$ 180,000
Payment of patent prosecution costs		$ 15,000
Number of common stock shares issued		31,550
Value of common stock shares		$ 78,875
Share issued price per share		$ 2.50	$ 2.50
License cost		$ 302,915	$ 302,915
Kotzker Consulting LLC [Member] | License Agreement [Member]
Capitalized legal fees		$ 29,040

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Sep. 02, 2017	Aug. 31, 2017	Aug. 25, 2017	Aug. 10, 2017	Aug. 10, 2017	Jul. 31, 2017	Mar. 31, 2018	Jan. 31, 2018	Jun. 30, 2017	May 31, 2017	May 30, 2017	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2018	Mar. 30, 2018
Value of common stock shares													$ 201,228
Gross proceeds of stock													582,500	$ 1,527,583
Common stock subscription value									$ 484,000				$ 484,000
Value of common stock shares issued for services														$ 55,350
Two Unrelated Individuals [Member] | Consulting Agreements [Member]
Stock price per share			$ 0.125
Agreement term			3 months
Number of common stock shares issued for services			442,800
Value of common stock shares issued for services			$ 55,350
Unrelated Individual One [Member] | Consulting Agreements [Member]
Number of common stock shares issued for services			304,800
Unrelated Individual Two [Member] | Consulting Agreements [Member]
Number of common stock shares issued for services			138,000
2017 Stock Incentive Plan [Member]
Number of common stock shares issued														1,833,341
Value of common stock shares														$ 229,168
2017 Stock Incentive Plan [Member] | Five Officers and Directors [Member]
Number of common stock shares issued				6,400,000	6,400,000
Value of common stock shares				$ 800,000	$ 800,000
Stock price per share				$ 0.125	$ 0.125
Stock option plan description				One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017.	One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017
2017 Stock Incentive Plan [Member] | Chief Executive Officer [Member]
Number of shares cancelled unvested							1,166,667
2018 Equity Incentive Plan [Member]
Common stock reserved for issuance															8,000,000
BioPharma [Member]
Stock price per share								$ 2.10
Gross proceeds of stock								$ 25,200
Common stock description								Each Unit consisted of two shares of Common Stock and one Warrant
Number of units sold								12,000
Sales of stock								24,000
Agreement term								6 months
Warrants to purchase shares								1
BioPharma [Member] | Common Stock [Member]
Gross proceeds of stock		$ 422,500				$ 422,500
Number of units sold		338,000				338,000
Sales of stock		3,380,000				3,380,000
Private Placement [Member]
Relative fair value of common stock								$ 19,762			$ 1,139,573
Fair value of warrants								$ 5,438			$ 255,927
Number of warrants issued								12,000
Private Placement [Member] | BioPharma [Member]
Gross proceeds of stock	$ 25,000
Sales of stock	100,000
Sale of stock, price per share	$ 0.25
Offering cost	$ 4,917
Intiva USA [Member]
Number of common stock shares issued														24,000,000
Value of common stock shares														$ 172,915
Common Stock [Member]
Number of common stock shares issued													24,000,000
Value of common stock shares													$ 2,400
Gross proceeds of stock									$ 973,000					$ 484,000
Number of units sold									778,400
Sales of stock									778,400
Common stock shares, subscribed units									387,200				387,200
Common stock shares subscription but not issued									3,872,000				3,872,000
Common stock subscription value									$ 484,000				$ 484,000
Common stock subscription receivable									$ 484,000				$ 484,000
Number of common stock shares issued for services														442,800
Value of common stock shares issued for services														$ 44
Common Stock [Member] | BioPharma [Member]
Stock price per share								$ 2.90
Warrants to purchase shares								2
Common Stock [Member] | Private Placement [Member]
Number of common stock and warrant units										1,116,400
Stock price per unit										$ 1.25
Common stock description										Each unit consisted of ten shares of Common Stock.
Common Stock [Member] | Private Placement [Member] | Common Class A [Member]
Stock price per unit										$ 0.25
Common Stock [Member] | Private Placement [Member] | Common Class B [Member]
Stock price per unit										0.38
Common Stock [Member] | Private Placement [Member] | Common Class C [Member]
Stock price per unit										$ 0.50
Common Stock [Member] | Private Placement [Member] | BioPharma [Member]
Number of common stock shares issued										831,112
Stock price per share										$ 0.1125
Gross proceeds of stock										$ 93,500
Proceeds from offering										$ 6,545
Common Stock [Member] | May 2017 Private Placement [Member]
Number of common stock shares issued														1,801,200
Common Stock [Member] | Intiva USA [Member]
Number of common stock shares issued												24,000,000
Value of common stock shares												$ 201,228

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Exercised (Details)	3 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Common Class A [Member]
Warrants Exercised, Shares | shares	960,400
Warrants, Exercise Price | $ / shares	$ 0.25
Gross Proceeds from Warrants | $	$ 240,100
Common Class B [Member]
Warrants Exercised, Shares | shares	746,800
Warrants, Exercise Price | $ / shares	$ 0.38
Gross Proceeds from Warrants | $	$ 283,784
Common Class C [Member]
Warrants Exercised, Shares | shares	94,000
Warrants, Exercise Price | $ / shares	$ 0.50
Gross Proceeds from Warrants | $	$ 47,000

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Warrant Activity (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2018
Number of shares, Outstanding beginning balance		2,335,200
Number of shares, Granted	2,335,200	1,026,000
Number of shares, Exercised		(1,801,200)
Number of shares, Expired		(525,600)
Number of shares, Outstanding ending balance	2,335,200	1,034,400
Number of shares, Exercisable	2,335,200	1,034,400
Weighted Average Exercise Price, Outstanding beginning balance	$ 0.38	$ 0.38
Weighted Average Exercise Price, Granted		0.41
Weighted Average Exercise Price, Exercised		0.32
Weighted Average Exercise Price, Expired		0.34
Weighted Average Exercise Price, Outstanding ending balance	0.38	0.53
Weighted Average Exercise Price, Exercisable	$ 0.38	$ 0.53
Weighted Average Remaining Contractual Term (Years)		6 months 10 days
Weighted Average Remaining Contractual Term (Years), Exercisable	6 months 10 days	1 month 6 days

Stockholders' Equity - Schedu26

Stockholders' Equity - Schedule of Warrants Outstanding (Details)	12 Months Ended
	Jun. 30, 2018$ / sharesshares
January 2018 Placement [Member]
Warrants Outstanding, Shares | shares	12,000
Warrants Outstanding, Exercise Price | $ / shares	$ 2.90
Warrants Outstanding, Expires	Jul. 15, 2018
May 2017 - Class C [Member]
Warrants Outstanding, Shares | shares	1,022,400
Warrants Outstanding, Exercise Price | $ / shares	$ 0.50
Warrants Outstanding, Expires	Aug. 8, 2018

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Aug. 10, 2017	Aug. 10, 2017	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018
Value of common stock shares issued				$ 201,228
Due from related parties				141,329	$ 15,000
Repaid to related party					$ 26,662
2017 Stock Incentive Plan [Member]
Number of common stock shares issued					1,833,341
Value of common stock shares issued					$ 229,168
2017 Stock Incentive Plan [Member] | Five Officers and Directors [Member]
Number of common stock shares issued	6,400,000	6,400,000
Value of common stock shares issued	$ 800,000	$ 800,000
Stock price per share	$ 0.125	$ 0.125
Stock option plan description	One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017.	One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017
2017 Stock Incentive Plan [Member] | Chief Executive Officer [Member]
Number of shares cancelled unvested			1,166,667
Intiva USA [Member]
Number of common stock shares issued					24,000,000
Value of common stock shares issued					$ 172,915
Due from related parties				$ 141,329	114,667
Repayments of debt					$ 1,500
Debt maturity date					Mar. 1, 2020
Intiva Kotzker [Member]
Ownership percentage					100.00%
Cost and expenses					$ 201,228
Kotzker Consulting [Member]
Value of common stock shares issued					78,875
Legal cost					$ 94,040

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Jun. 30, 2018USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 1,534,000
Operating loss carryforwards expiration date description	The available net operating loss carry forwards expire in various years through 2038.

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Asset (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 568,734	$ 70,945
Valuation allowance	(568,734)	(70,945)
Total

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Change in net operating loss benefit	$ 497,789	$ 70,945
Change in valuation allowance	(497,789)	(70,945)
Total

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - $ / shares	Sep. 12, 2018	Jul. 27, 2018	Aug. 31, 2018	Jul. 31, 2018	Jul. 25, 2018
Warrant to purchase common stock description		Each new warrant, denominated as Class D, is exercisable through September 28, 2018 (subsequently extended to November 30, 2018) to purchase one unit for $1.00, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock at a price of $2.00 per share through January 31, 2019.
Class C Warrants [Member]
Warrant expiration date		Company extended the expiration date of its Class C Warrants, from July 27, 2018, to August 8, 2018.
Class D Warrants [Member]
Number of warrants issued		976,400
Class E Warrants [Member]
Warrant to purchase common stock description	Each Class E warrant is exercisable to purchase one share of common stock at a price of $2.00 per share through January 31, 2019.
Number of warrant authorized	94,000
Warrants, Exercise Price	$ 2
Chief Executive Officer and Chief Financial Officer [Member]
Number of unvested shares of common stock					1,083,342
Officers / Directors / Consultants [Member] | 2018 Equity Incentive Plan [Member]
Number of options to purchase shares of common stock				1,810,000
Options exercisable term				7 years
Options exercise price per share				$ 0.54
Two Individuals [Member] | 2018 Equity Incentive Plan [Member]
Number of options to purchase shares of common stock			150,000
Options exercisable term			7 years
Options exercise price per share			$ 0.38